Arranta Bio, part of Recipharm’s biologics business, has signed a contract with MIT to develop a continuous manufacturing technology for mRNA therapeutics. The contract is part of the FDA’s initiative to have a fully integrated, continuous manufacturing production line for mRNA vaccines, which the agency is funding through a contract to MIT – one of the largest awards from the FDA’s CBER office. Enabling rapid manufacturing capacity aims to provide faster readiness and reaction to new pandemic t...